TY - JOUR
T1 - p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy
AU - Coradini, Danila
AU - Biganzoli, Elia
AU - Ardoino, Ilaria
AU - Ambrogi, Federico
AU - Boracchi, Patrizia
AU - Demicheli, Romano
AU - Daidone, Maria Grazia
AU - Moliterni, Angela
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Genomic analysis and protein expression assimilate triple-negative breast cancers (TNBC) with basal-like breast tumors. TNBCs, however, have proved to encompass also tumors with normal-like phenotype and known to have favorable prognosis and to respond to chemotherapy. In a recent paper, we have provided evidence that p53 status is able to subdivide TNBCs into two distinct subgroups with different outcome, and consistent with basal- and normal-like phenotypes. Based on this finding, we explored the contribution of p53 status in predicting the response to adjuvant CMF or CMF followed doxorubicin chemotherapy of a group of TNBC patients. Results indicated that TNBC patients with a p53-positive tumor had a shorter relapse-free and overall survival than patients carrying a p53-negative TNBC, corroborating our hypothesis about the relationship between TNBC phenotype (basal-like versus normal-like) and p53 status as predictor of response to antracycline/CMF-based chemotherapy.
AB - Genomic analysis and protein expression assimilate triple-negative breast cancers (TNBC) with basal-like breast tumors. TNBCs, however, have proved to encompass also tumors with normal-like phenotype and known to have favorable prognosis and to respond to chemotherapy. In a recent paper, we have provided evidence that p53 status is able to subdivide TNBCs into two distinct subgroups with different outcome, and consistent with basal- and normal-like phenotypes. Based on this finding, we explored the contribution of p53 status in predicting the response to adjuvant CMF or CMF followed doxorubicin chemotherapy of a group of TNBC patients. Results indicated that TNBC patients with a p53-positive tumor had a shorter relapse-free and overall survival than patients carrying a p53-negative TNBC, corroborating our hypothesis about the relationship between TNBC phenotype (basal-like versus normal-like) and p53 status as predictor of response to antracycline/CMF-based chemotherapy.
KW - Adjuvant chemotherapy
KW - Breast cancer
KW - P53 status
KW - Triple negative
UR - http://www.scopus.com/inward/record.url?scp=84937637754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937637754&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2015.01.007
DO - 10.1016/j.breast.2015.01.007
M3 - Article
C2 - 25698149
AN - SCOPUS:84937637754
VL - 24
SP - 294
EP - 297
JO - Breast
JF - Breast
SN - 0960-9776
IS - 3
ER -